Dr Chan Ching Wan
Senior Consultant & Breast Surgeon
MBChB (Edin), FRCS (Edin), FRCS (Glas), PhD (Bristol)
Languages: English, Mandarin
Training and Qualifications
Dr Chan obtained her medical degree from the University of Edinburgh Medical School. Subsequently, Dr Chan completed both basic and advanced specialty training in general surgery at the Singapore General Hospital, and exited from the programme in 2007. She has been a fellow of the Royal College of Surgeons of Edinburgh, and a fellow of the Royal College of Physicians and Surgeons of Glasgow since 1999. In the midst of her surgery training, Dr Chan received an NMRC Totalisator Board Scholarship where she completed her PhD in Neuroendocrinology at the University of Bristol in 2004.
Awarded the HMDP Award and Skills Attachment Award
In 2008, Dr Chan received the Health Manpower Development Program (HMDP) Award as an oncoplastic Breast Fellow in Nottingham Breast Institute, UK. She is trained in the procedures of therapeutic mammoplasty, latissimus dorsi flap for partial and total breast reconstruction, implant reconstruction, contralateral symmetrisation surgery, and the transfer of fat for volume deficits and contour remodelling. Additionally, Dr Chan helped develop transitional studies aimed at various aspects of cancer diagnosis, detection, and treatment.
As she pursued her interests and education, she also received a Skills Attachment Award in contrast-enhanced digital mammography (team AMDA Award) in 2018.
Read Articles By Dr Chan Ching Wan
Optoacoustic characterization of breast conserving surgery specimens – A pilot study.
Balasundaram G, Goh Y, Moothanchery M, Attia A, Lim HQ, Burton NC, Olivo M, Chan CW.
PHOTOACOUSTICS. 2020; 19: 9 pages.
DOI: 10.1016/j.pacs.2020.100164
Maintaining breast cancer care in the face of COVID-19.
Ng CWQ, Tseng M, Lim JSJ, Chan CW.
Br J Surg. 2020; 107(10): 1245-1249.
DOI: 10.1002/bjs.11835
European polygenic risk score for prediction of breast cancer shows similar performance in Asian women.
Ho WK, Tan MM, Mavaddat N, Tai MC, Mariapun S, Li J, Antoniou AC, Chan CW.
Nat Commun. 2020; 11(1): 11 pages.
DOI:10.1038/s41467-020-17680-w
Ultrasound Guided Optoacoustic Tomography in Assessment of Tumor Margins for Lumpectomies.
Goh Y, Balasundaram G, Moothanchery M, Attia A, Li X, Lim HQ, Olivo M, Chan CW.
Transl Oncol. 2020; 13(2): 254-261.
DOI: 10.1016/j.tranon.2019.11.00
Barcoded DNA nanostructures for the multiplexed profiling of subcellular protein distribution.
Sundah NR, Ho NRY, Lim GS, Natalia A, Ding X, Liu Y, Shao H, Chan CW.
Nat Biomed Eng. 2019; 3(9): 684-694.
DOI: 10.1038/s41551-019-0417-0
The functional ALDH2 polymorphism is associated with breast cancer risk: A pooled analysis from the Breast Cancer Association Consortium.
Ugai T, Milne RL, Ito H, Aronson KJ, Bolla MK, Chan T, Matsuo K, Chan CW.
Mol Genet Genomic Med. 2019; 7(6): e00696.
DOI: 10.1002/mgg3.707
Investing in gender equity in health and biomedical research: a Singapore perspective.
Yoong J, Alonso S, Chan CW, Clement MV, Lim LHK, Archuleta S.
Lancet. 2019; 393(10171): e21-e22.
Multispectral Optoacoustic Tomography in Assessment of Breast Tumor Margins During Breast-Conserving Surgery: A First-in-human Case Study.
Goh Y, Balasundaram G, Moothanchery M, Attia A, Li X, Lim HQ, Olivo M, Chan CW.
Clin Breast Cancer. 2018; 18(6): e1247-e1250.
DOI: 10.1016/j.clbc.2018.07.026
A genome-wide association study identifies three novel genetic markers for response to tamoxifen: A prospective multicenter study.
Onishi H, Udagawa C, Kubo M, Nakamura S, Akashi-Tanaka S, Kuwayama T, Zembutsu H, Chan CW.
PLoS One. 2018; 13(8): e0208701.
DOI: 10.1371/journal.pone.0201606
Ductal carcinoma in-situ arising within benign phyllodes tumours.
Lui SA, Oh HB, Wang S, Chan CW.
Ann R Coll Surg Engl. 2018; 100(4): e97-e102.
DOI: 10.1308/rcsann.2018.0024
Triple negative breast cancer in Asia: An insider’s view.
Wang C, Kar S, Lai X, Cai W, Arfuso F, Sethi G, Kumar AP, Chan CW.
Cancer Treat Rev. 2018; 62: 29-38.
Significant Effect of Polymorphisms in CYP2D6 on Response to Tamoxifen Therapy for Breast Cancer: A Prospective Multicenter Study.
Zembutsu H, Nakamura S, Akashi-Tanaka S, Kuwayama T, Watanabe C, Takamaru T, Nakamura Y, Chan CW.
Clin Cancer Res. 2017; 23(8): 2019-2026.
DOI: 10.1158/1078-0432.CCR-16-1779
Genomic predictors of neoadjuvant chemotherapy (NACT) response in breast cancer (BC).
Wong ALA, Tan KT, Sundar R, Ow S, Pang A, Yap HL, Lee SC, Chan CW.
J Clin Oncol. 2017; 35(15 suppl): e12075.
DOI: 10.1200/JCO.2017.35.15_suppl.e1212
Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer.
Wong ALA, Sundar R, Wang TT, Ng TC, Zhang B, Tan SH, Lee SC, Chan CW.
Oncotarget. 2016; 7(39): 64089-64099.
DOI: 10.18632/oncotarget.11596
High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer.
Wang T, Srivastava S, Hartman M, Buhari SA, Chan CW, Iau P, Lee SC.
Oncotarget. 2016; 7(34): 55155-55168.
DOI: 10.18632/oncotarget.10894
Considerations regarding lipofilling in patients after breast cancer.
Chan CW.
J Plast Reconstr Aesthet Surg. 2016; 69(5): e103-e104.
DOI: 10.1016/j.bjps.2016.01.016
Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.
Wang T, Seah S, Loh X, Chan CW, Hartman M, Goh BC, Lee SC.
Oncotarget. 2016; 7(3): 2532-2544.
Accelerated partial breast irradiation in an Asian population: dosimetric findings and preliminary results of a multicatheter interstitial program.
Koh YV, Tan PW, Buhari SA, Iau P, Chan CW, Shen L, Tang JIH.
Onco Targets Ther. 2016; 9: 5561-5566.
DOI: 10.2147/OTT.S106758
Genomic landscapes of breast fibroepithelial tumors.
Tan J, Ong CK, Lim WK, Ng CCY, Thike AA, Ng LM, Teh BT, Chan CW.
Nat Genet. 2015; 47(11): 1341-1345.
DOI:10.1038/ng.3409
Cell viability and angiogenic potential of a bioartificial adipose substitute.
Panneerselvan A, Nguyen LTH, Su Y, Teo WE, Liao S, Ramakrishna S, Chan CW.
J Tissue Eng Regen Med. 2015; 9(6): 702-713.
DOI: 10.1002/term.1633
Differential cell adhesion of breast cancer stem cells on biomaterial substrate with nanotopographical cues.
Tan KKB, Giam CSY, Leow MY, Chan CW, Yim EKF.
J Funct Biomater. 2015; 6(2): 241-258.
DOI: 10.3390/jfb6020241
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.
Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, Easton DF, Chan CW.
Nat Genet. 2015; 47(4): 373-380.
DOI:10.1038/ng.3242
Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium.
Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menendez-Rodriguez P, Easton DF, Chan CW.
Hum Mol Genet. 2014; 23(22): 6096-6111.
Simvastatin induced apoptosis and suppressed proliferation of breast cancer through deactivating PI3K/Akt/mTOR pathway.
Wang T, Seah S, Chan CW, Hartman M, Dar NNT, Iau P, Lee SC.
Cancer Res. 2014; 74(19 Suppl): Abstract nr 1681.
DOI: 10.1158/1538-7445.AM2014-2630
Phase II study of neoadjuvant weekly paclitaxel and carboplatin with lapatinib in HER2+ breast cancer.
Wong ALA, Tan SH, Soh IPT, Tan CS, Lim YW, Pang A, Lee SC, Chan CW.
J Clin Oncol. 2014; 32(15_suppl): 616.
DOI: 10.1200/jco.2014.32.15_suppl.619
Effect of low-dose, short-course sunitinib (Su) on tumor vasculature and tumor blood flow for enhancement of chemotherapy efficacy in breast cancer.
Wong ALA, Sundar R, Ow SGW, Wang TT, Ng TC, Chan CW, Lee SC.
J Clin Oncol. 2014; 32(15_suppl): e22053.
DOI: 10.1200/jco.2014.32.15_suppl.1060
Genome-wide association studies identify four ER negative-specific breast cancer risk loci.
Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Kraft P, Chan CW.
Nat Genet. 2013; 45(4): 392-398.
DOI:10.1038/ng.2561
Low-dose, short-course sunitinib may normalize tumor vasculature and improve tumor blood flow to enhance chemotherapy efficacy in breast cancers.
Lee SC, Wong ALA, Ng TC, Thng CH, Wang TT, Tiemsim MC, Goh BC, Chan CW.
J Clin Oncol. 2012; 30(15_suppl): e13520.
DOI: 10.1200/jco.2012.30.15_suppl.1064
Extracellular matrix protein expression is associated with chemotherapy resistance in breast cancer.
Wang T, Guo T, Sze SK, Hartman M, Buhari SA, Chan CW, Lee SC.
Cancer Res. 2012; 72(8 Suppl): Abstract nr 1702.
DOI: 10.1158/1538-7445.AM2012-2460
Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy.
Chuah BYS, Putti T, Salto-Tellez M, Charlton A, Iau P, Buhari SA, Lee SC, Chan CW.
Ann Oncol. 2011; 22(8): 1748-1754.
DOI: 10.1093/annonc/mdq755
A Commentary on Delayed Presentation of Breast Cancer in Singapore.
Chang G, Chan CW, Hartman M.
Asian Pac J Cancer Prev. 2011; 12(6): 1635-1639.
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Lim YW, Goh BC, Wang LZ, Tan SH, Chuah BYS, Lim SE, Lee SC, Chan CW.
Ann Oncol. 2010; 21(11): 2175-2182.
DOI: 10.1093/annonc/mdq230
Autologous fat transfer – a review of the literature with a focus on breast cancer surgery.
Chan CW, McCulley SJ, Macmillan RD.
J Plast Reconstr Aesthet Surg. 2008; 61(12): 1438-1448.
DOI: 10.1016/j.bjps.2008.08.006
Volume displacement techniques and therapeutic mammoplasty: The Nottingham experience.
Macmillan RD, Chan CW, McCulley SJ.
Adv Breast Cancer. 2008; 5(1): 10-12.
A novel member of the SAF (scaffold attachment factor)-box protein family inhibits gene expression and induces apoptosis.
Chan CW, Lee YB, Uney J, Flynn A, Tobias JH, Norman M.
Biochem J. 2007; 407(3): 355-362.
DOI: 10.1042/BJ20070170